Who Exports Ritonavir from India — 84 Suppliers Behind a $340.6M Market
India's ritonavir export market is supplied by 84 active exporters who collectively shipped $340.6M across 1,555 shipments. HETERO LABS LIMITED leads with a 56.9% market share, followed by MYLAN LABORATORIES LIMITED and CIPLA LIMITED. The top 5 suppliers together control 96.9% of total export value, reflecting a concentrated market structure.
Top Ritonavir Exporters from India — Ranked by Export Value
HETERO LABS LIMITED is the leading ritonavir exporter from India, holding a 56.9% share of the $340.6M market across 1,555 shipments from 84 exporters. The top 5 suppliers — HETERO LABS LIMITED, MYLAN LABORATORIES LIMITED, CIPLA LIMITED, EMCURE PHARMACEUTICALS LIMITED, AUROBINDO PHARMA LTD — collectively control 96.9% of total export value, indicating a highly concentrated market. Individual shares are: HETERO LABS LIMITED (56.9%), MYLAN LABORATORIES LIMITED (27.0%), CIPLA LIMITED (7.1%), EMCURE PHARMACEUTICALS LIMITED (4.5%), AUROBINDO PHARMA LTD (1.4%).
Top Ritonavir Exporters from India
Ranked by export value · 84 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | HETERO LABS LIMITED LOPINAVIR 200 MG + RITONAVIR 50 MG TABLETSRITONAVIR TABLETANZAVIR-R TABLETS | $193.8M | 81 | 56.9% |
| 2 | MYLAN LABORATORIES LIMITED LOPINAVIR 200 MG + RITONAVIR 50 MG TABLETSRITONAVIR TABLETANZAVIR-R TABLETS | $92.0M | 92 | 27.0% |
| 3 | CIPLA LIMITED LOPIMUNE 200/50MG TABLETSLOPINAVIR 200 MG + RITONAVIRRILOVIA LOPINAVIR 200 MG + RITONAVIR | $24.1M | 10 | 7.1% |
| 4 | EMCURE PHARMACEUTICALS LIMITED LOPINAVIR 200 MG + RITONAVIR 50 MG TABLETSATAZANAVIR 300MG + RITONAVIR 100MG) TABLANZAVIR-R TABLETS - NO CARTON | $15.2M | 43 | 4.5% |
| 5 | AUROBINDO PHARMA LTD ANZAVIR-R TABLETSATAZANAVIR 300MG + RITONAVIR 100MG) TABLANZAVIR-R TABLETS - NO CARTON | $4.9M | 39 | 1.4% |
| 6 | EMCURE PHARMACEUTICALS LTD LOPINAVIR 200 MG + RITONAVIR 50 MG TABLETSATAZANAVIR 300MG + RITONAVIR 100MG) TABLANZAVIR-R TABLETS - NO CARTON | $3.5M | 7 | 1.0% |
| 7 | AUROBINDO PHARMA LIMITED ANZAVIR-R TABLETSATAZANAVIR 300MG + RITONAVIR 100MG) TABLANZAVIR-R TABLETS - NO CARTON | $2.4M | 26 | 0.7% |
| 8 | MACLEODS PHARMACEUTICALS LTD LOPINAVIR 200 MG + RITONAVIR 50 MG TABLETSLOPINAVIR AND RITONAVIR TABLETS 200 50 MLOPINAVIR AND RITONAVIR TABLETS 200+50MG | $2.0M | 11 | 0.6% |
| 9 | LIVEALTH BIOPHARMA PRIVATE LIMITED | $399.9K | 2 | 0.1% |
| 10 | GLOBELA PHARMA PRIVATE LIMITED | $276.5K | 2 | 0.1% |
| 11 | AAGAMA EXPORTS LLP | $193.0K | 1 | 0.1% |
| 12 | MACLEODS PHARMACEUTICALS LIMITED LOPINAVIR 200 MG + RITONAVIR 50 MG TABLETSLOPINAVIR AND RITONAVIR TABLETS 200 50 MLOPINAVIR AND RITONAVIR TABLETS 200+50MG | $160.8K | 2 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ritonavir exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| HETERO LABS LIMITED | Approved | Yes | Yes | Multiple | Hetero Labs Ltd has received WHO prequalification for Dolutegravir (sodium) 50mg |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | Mylan Laboratories Ltd has received WHO prequalification for Efavirenz 50mg tabl |
| CIPLA LIMITED | Approved | Yes | Yes | Multiple | Cipla Ltd is listed among WHO GMP certified companies in India. |
| EMCURE PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Emcure Pharmaceuticals Ltd has received WHO prequalification for Atazanavir (sul |
| AUROBINDO PHARMA LTD | Approved | Yes | Yes | Multiple | Aurobindo Pharma Ltd has received WHO prequalification for Dolutegravir (sodium) |
| MACLEODS PHARMACEUTICALS LTD | Approved | Yes | Yes | Multiple | Macleods Pharmaceuticals Ltd has received WHO prequalification for Artemether/Lu |
| MICRO LABS LIMITED | Approved | Yes | Yes | Multiple | Micro Labs Ltd is listed among WHO GMP certified companies in India. |
| AUROBINDO PHARMA LIMITED | Approved | Yes | Yes | Multiple | Aurobindo Pharma Ltd has received WHO prequalification for Dolutegravir (sodium) |
| MACLEODS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | Macleods Pharmaceuticals Ltd has received WHO prequalification for Artemether/Lu |
TransData Nexus reviewed the regulatory standing of 9 leading Ritonavir exporters from India. 9 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ritonavir sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a central hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts numerous pharmaceutical companies, including Aurobindo Pharma Limited, which is headquartered in Hyderabad. Aurobindo Pharma is a significant exporter of Ritonavir, contributing $4.9 million (1.4%) to the total exports. The city's well-established infrastructure and skilled workforce make it a critical node in the supply chain for APIs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to several leading pharmaceutical companies, including Cipla Limited, which has a notable presence in the area. Cipla is a key exporter of Ritonavir, accounting for $24.1 million (7.1%) of the total exports. The cluster's emphasis on formulations complements the API production in other regions, ensuring a seamless supply chain from raw materials to finished products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. This region's proximity to major ports facilitates efficient international distribution. Companies like Cipla Limited, headquartered in Mumbai, leverage this strategic location to export Ritonavir and other pharmaceuticals to global markets. The area's robust logistics infrastructure supports the high volume of pharmaceutical exports originating from this cluster.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, initially attracting companies through tax incentives. The region hosts numerous pharmaceutical units, including those of Cipla Limited. Although the initial tax benefits have phased out, the established manufacturing ecosystem continues to support significant production capacities. Baddi's contribution to the pharmaceutical supply chain underscores its importance in the overall industry landscape.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 96.9% of Ritonavir exports, it's advisable to diversify sourcing to mitigate risks associated with supplier concentration.
- Leverage Regional Specializations: Utilize the strengths of different pharmaceutical clusters—such as Hyderabad for APIs and Ahmedabad-Vadodara for formulations—to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
- Assess Logistics Infrastructure: Evaluate the logistics capabilities of each region, particularly export gateways like Mumbai-Thane-Raigad, to ensure efficient distribution channels.
By strategically engaging with India's diverse pharmaceutical clusters, companies can enhance the resilience and efficiency of their Ritonavir supply chains.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ritonavir exporters from India
Aurobindo Pharma Limited — Aurobindo Pharma receives FDA approval for Deutetrabenazine Tablets
On December 26, 2024, the U.S. Food and Drug Administration (FDA) approved Aurobindo Pharma's Abbreviated New Drug Application (ANDA) for Deutetrabenazine Tablets, indicated for the treatment of chorea associated with Huntington's disease. - IMPACT: This approval may enhance Aurobindo's market presence, potentially influencing its Ritonavir export capabilities.
Impact: This approval may enhance Aurobindo's market presence, potentially influencing its Ritonavir export capabilities.
Hetero Labs Limited — Hetero Labs secures FDA approval for Raltegravir Tablets
On December 19, 2024, the FDA approved Hetero Labs' ANDA for Raltegravir Tablets USP, used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients. - IMPACT: This approval may bolster Hetero's antiretroviral portfolio, potentially affecting its Ritonavir export dynamics.
Impact: This approval may bolster Hetero's antiretroviral portfolio, potentially affecting its Ritonavir export dynamics.
Emcure Pharmaceuticals Limited — Emcure Pharmaceuticals files Draft Red Herring Prospectus for IPO
In December 2023, Emcure Pharmaceuticals submitted a Draft Red Herring Prospectus to the Securities and Exchange Board of India (SEBI) for its proposed Initial Public Offering (IPO). - IMPACT: The IPO aims to raise capital for expansion, which could influence Emcure's Ritonavir production and export strategies.
Impact: The IPO aims to raise capital for expansion, which could influence Emcure's Ritonavir production and export strategies.
Common Questions — Ritonavir Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ritonavir supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, HETERO LABS LIMITED leads with 494 recorded shipments worth $193.8M. MYLAN LABORATORIES LIMITED (550 shipments) and CIPLA LIMITED (28 shipments) are also established high-volume exporters.
Q How many ritonavir manufacturers are there in India?
India has 84 active ritonavir exporters with a combined export market of $340.6M across 1,555 shipments to 155 countries. The top 5 suppliers hold 96.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ritonavir from India?
Average FOB unit price: $20.57 per unit, ranging from $0.00 to $2500.00. Average shipment value: $219.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 84 verified Indian exporters of Ritonavir ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,555 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 155 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,555 Verified Shipments
84 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists